openPR Logo
Press release

Adrenocortical Carcinoma Treatment Market 2017 Industry Analysis, Segment & Forecast up to 2025

04-27-2018 04:50 PM CET | Health & Medicine

Press release from: CMI Research Report

Adrenocortical Carcinoma Treatment Market 2017 Industry

Adrenocortical carcinoma is a rare cancer affecting the outer layer of the adrenal glands, which are responsible for producing certain hormones and maintaining optimum blood pressure levels. Adrenocortical carcinoma is relatively frequent in children compared to other cancers, although the cancer may also affect adults. The most common symptoms of adrenocortical carcinoma include abdominal pain, hypertension, weight gain, and frequent urination, which are mainly caused due to tumors causing excess secretion of hormones from the adrenal glands. Mitotane is the only drug approved by the U.S. Food and Drug Administration (FDA) and European Medicine Executive Agency (EMEA) for treatment of metastatic adrenocortical carcinoma. According to the study by HealthLine Media, 2017, about 5-10% of the adrenal tumors are malignant. Diagnosis of adrenocortical carcinoma is based on urine tests, dexamethasone suppression test for detecting abnormal levels of cortisol, which is the hormone released by the adrenal glands. Also, a wide number of imaging devices are used for diagnoses of the disease, which includes CT scan, MRI, PET scan, and MIBG Scan, thus aiding for faster disease identification that aids the doctors to decide for further treatments.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1551

Adrenocortical Carcinoma Treatment Market: Market Dynamics

Increasing incidence of adrenocortical carcinoma associated with genetic disorders is a major factor augmenting growth of the adrenocortical carcinoma treatment market. According to the Journal of Clinical Endocrinology & Metabolism, 2013, the peak incidence of adrenocortical carcinoma ranges between 40-50 years, where women are 55–60% more likely to get affected with a ratio of ratio 1.5:1. The study also states that adrenocortical carcinoma is a rare and highly aggressive malignancy with an annual incidence of 0.05–0.2% or 1-2 cases per million population globally. Also, inherited disorders such as Li-Fraumeni syndrome (LFS), Beckwith-Wiedemann syndrome (BWS), and Carney complex are linked with increasing incidence of adrenocortical carcinoma. According to the survey by Endocrine Society, 2014, adrenocortical carcinoma comprises an approximate 3% to 10% of malignancies in LFS and over 5-15% of malignancies in BWS. Moreover, according to the study by Medscape, 2017, adrenocortical carcinoma accounted for 0.02-0.2% of all cancer-related deaths, globally.

Moreover, number of clinical trials are increasing for different chemotherapeutics by various organizations and manufacturers. For instance, Millendo Therapeutics, Inc., initiated the Phase 1 trial for ATR-101 in 2013 to treat adrenocortical carcinoma. Also, the National Cancer Institute initiated a Phase 2 trial for Phase II trial of Cisplatin and sodium thiosulfate for surgical resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for adrenocortical carcinoma. Also, in March 2018, the University of Colorado Anschutz Medical Campus presented new models to identify genetic targets and test promising treatments in adrenocortical carcinoma at the ENDO Conference, thus exploring new therapeutic options for the patients.

Adrenocortical Carcinoma Treatment Market: Regional Dynamics

Regional segmentation of the global adrenocortical carcinoma treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global adrenocortical carcinoma treatment market over the forecast period, owing to rise in prevalence of the disease and presence of key players that are focusing on developing novel products, followed by Europe, the next dominating adrenocortical carcinoma treatment market. According to the National Institutes of Health Office of Rare Diseases Research, the incidence rate of adrenal cancer is about 600 new cases per year in the U.S. Moreover, organizations such as the University of Michigan Rogel Cancer Center are involved in stem cell research, to advance treatment in adrenal cancer.

Request for complete TOC of this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1551

Latin America is expected to gain significant traction in the forecast period, owing to higher incidence rate of the condition in Brazil. According to the survey ACC C.U.R.E. Organization, adrenal cancer in Brazil is 15 times more prevalent than any other countries in the world, attributed to high prevalence of mutation of a single gene TP53. Also, according to the Endocrine Society, 2014, the incidence during childhood is 2.9 to 4.2 per million per year in Brazil compared with an estimated incidence of 0.2 to 0.3 per million children per year worldwide. Moreover, the University of Michigan has been collaborating with the Adrenal Cancer Group in Sao Paulo to bring about the advancements in adrenal cancer research, thus providing better clinical outcomes for patients in the region.

Adrenocortical Carcinoma Treatment Market: Competitive Analysis

Manufactures are focused on launching novel therapeutic products for treatment of these rare diseases, thus accelerating market growth. For instance, in 2017, the FDA approved immunotherapy drug Keytruda (Pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy, developed by Merck & Co., indicated for advanced adrenocortical carcinoma.

Key players operating in the global adrenocortical carcinoma treatment market include ArQule, Inc., EnGeneIC Ltd., Exelixis, Inc., Merck & Co., Millendo Therapeutics, and Orphagen Pharmaceuticals, Inc.

Adrenocortical Carcinoma Treatment Market:Market Taxonomy

On the basis of therapy type, the global adrenocortical carcinoma treatment market is segmented into: Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy,.

On the basis of disease type, the global adrenocortical carcinoma treatment market is segmented into: Localized adrenocortical carcinoma, Metastatic adrenocortical carcinoma,.

On the basis of end user, the global adrenocortical carcinoma treatment market is segmented into: Hospital, Clinics, Ambulatory Surgical Centers,.

Complete Report Details @ https://www.coherentmarketinsights.com/ongoing-insight/adrenocortical-carcinoma-treatment-market-1551

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Adrenocortical Carcinoma Treatment Market 2017 Industry Analysis, Segment & Forecast up to 2025 here

News-ID: 1033758 • Views:

More Releases from CMI Research Report

Hospital Beds Market worth US$ 5.2 Billion by 2025 Globally
Hospital Beds Market worth US$ 5.2 Billion by 2025 Globally
Many of the hospitals have shifted their capital funds towards the hospital infrastructure, which is mainly seen in private hospitals. Improving healthcare amenities along with increasing spending in healthcare is expected to boost growth of hospitals beds market globally. Increasing number of geriatric population and need for their treatment is expected to fuel the growth of hospital bed market over the forecast period. The number of hospital beds are very
Acute Bacterial Skin and Skin Structure Infections Market Sales, Size, Leading Player & Forecast to 2025
Acute Bacterial Skin and Skin Structure Infections Market Sales, Size, Leading P …
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are the type of skin and soft tissue infections that affects the epidermis, dermis, and subcutaneous tissues. The US FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, and Pseudomonas
Primary Biliary Cirrhosis Drugs Market Overview, Trends and Growth Opportunities Forecasted till 2025
Primary Biliary Cirrhosis Drugs Market Overview, Trends and Growth Opportunities …
Primary biliary cirrhosis, known as primary biliary cholangitis is a chronic liver disease, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. Cause for primary biliary cirrhosis can be autoimmunity, infection and/or genetic predisposition. Symptoms of primary biliary cirrhosis includes itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation,
Orthopedic Medical Imaging Market Trends and Drivers Analysis 2017 - 2025
Orthopedic Medical Imaging Market Trends and Drivers Analysis 2017 - 2025
Orthopedic medical imaging allows doctors to non-invasively examine the internal structure of the body for aiding in diagnosing a medical condition. Medical imaging devices identify and monitor diseases or injuries by generating images representing internal anatomic structures of the patient's body. Orthopedic medical imaging has proved to be an informational tool that has helped physicians to diagnose the disease and response of the treatment. Orthopedic medical imaging deliver safe, effective,

All 5 Releases


More Releases for Adrenocortical

Adrenocortical Hormones API Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion
Adrenocortical Carcinoma Drugs Market Overview: Growth, Share, Value, Size, and …
The global Adrenocortical Carcinoma Drugs market is projected to reach approximately USD 0.85 billion by 2033, growing at a compound annual growth rate (CAGR) of around 7.2% from 2025 to 2033. Adrenocortical Carcinoma Drugs Market Overview The global Adrenocortical Carcinoma (ACC) drugs market is experiencing growth, driven by the increasing incidence of this rare endocrine malignancy and advancements in therapeutic approaches. ACC is characterized by aggressive tumor behavior and limited treatment options,
Adrenocortical Hormones API Market Survey Detailed Analysis and Forecast 2024-20 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion
Adrenocortical Carcinoma Treatment: Challenges, Advances, and Market Dynamics
Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer originating in the adrenal cortex, the outer layer of the adrenal glands. These glands, located above the kidneys, are responsible for producing hormones that regulate a variety of bodily functions, such as metabolism, blood pressure, and immune response. ACC is often diagnosed at an advanced stage due to its asymptomatic early course, and treatment options are limited. In this
Adrenocortical Hormones API Market Research Explores Revenue Share Study Analysi …
Adrenocortical Hormones API Market is valued at US$ 2.24 Billion in 2023, and it is expected to reach US$ 3.55 Billion by 2031, with a CAGR of 6.04 % during the forecast period of 2024-2031. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs,
Adrenocortical Hormones API Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Adrenocortical Hormones API market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Adrenocortical Hormones APImarket by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of Adrenocortical Hormones APImarket, market definition, overview, industry opportunities